Tredegar Corporation 10-K Summary: Fiscal Year Ended December 31, 2002
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2002. Tredegar Corporation operates primarily through two manufacturing segments: Film Products (plastic films, nonwovens, and laminates for personal care and packaging) and Aluminum Extrusions (soft-alloy aluminum for construction and industrial markets). The company also holds a biotechnology subsidiary, Therics (held for sale), and an investment subsidiary, Tredegar Investments, focused on high-risk venture capital stakes in technology start-ups.
Key Financial Metrics
| Metric | 2002 | 2001 |
|---|---|---|
| Net Sales | $737.4 million | $763.6 million |
| Net Income (Loss) | $(2.5) million | $9.8 million |
| Diluted EPS (Loss) | $(0.07) | $0.25 |
| Gross Profit Margin | 21.0% | 19.0% |
| Operating Cash Flow | $65.3 million | $74.9 million |
| Total Debt | $259.3 million | $264.5 million |
| Cash and Equivalents | $109.9 million | $96.8 million |
| Shareholders' Equity | $462.9 million | $477.9 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 3.4% to $737.4 million, driven by volume declines in Aluminum Extrusions due to weak economic conditions and lower volume in Film Products, partially offset by volume shortfall payments.
- Net Loss: The company reported a net loss of $2.5 million compared to net income of $9.8 million in 2001. This was primarily due to a $66.3 million pre-tax loss in Tredegar Investments (venture capital write-downs) and an $8.7 million loss from discontinued operations (Molecumetics).
- Margin Improvement: Despite lower sales, the gross profit margin improved to 21% from 19%, aided by higher-margin product sales in Film Products and fixed cost reductions in Aluminum Extrusions following plant shutdowns.
- Unusual Items: 2002 included a net gain of $2.3 million from unusual items, primarily a $5.6 million gain from contract terminations and revisions with Procter & Gamble (P&G), offset by asset impairment charges.
Guidance, Outlook, and Risks
- Divestitures: Management announced intent to divest Therics (biotech) and is exploring alternatives to maximize the after-tax value of the Tredegar Investments portfolio, including a potential secondary market sale. A decision on the investment portfolio is expected by March 31, 2003.
- Customer Concentration: P&G remains the largest customer, accounting for 33% of net sales in 2002. The company expects to lose approximately $60 million in domestic backsheet business from P&G by the end of Q1 2003.
- Outlook: Management expects Film Products operating profit to be around $12 million per quarter in the first half of 2003, with growth resuming in 2004 as new products launch. Aluminum Extrusions remains sensitive to cyclical economic downturns.
- Risks: Significant risks include the valuation uncertainty of venture capital investments, the potential failure to sell Therics, and the impact of losing P&G business without immediate replacement.
Investor Verification Checklist
- Venture Capital Valuation: Verify the methodology used to value private securities and the potential discount if the portfolio is sold in the secondary market.
- P&G Contract Status: Confirm the timeline and financial impact of the loss of P&G's domestic backsheet business and the progress of new product introductions to offset this loss.
- Divestiture Progress: Monitor updates on the sale of Therics and the strategic decision regarding the venture capital portfolio.
- Debt Covenants: Review the company's compliance with debt-to-capitalization ratios (currently 50% limit) given the volatility in investment asset values.
- Discontinued Operations: Assess the final costs associated with the closure of Molecumetics and any remaining liabilities.